Literature DB >> 2894394

CD3-negative lymphokine-activated cytotoxic cells express the CD3 epsilon gene.

R Biassoni1, S Ferrini, I Prigione, A Moretta, E O Long.   

Abstract

The expression of genes encoding different polypeptide chains of the TCR-CD3 complex was analyzed in a panel of cloned MHC-unrestricted cytotoxic cells. The clones were derived from CD3+ and CD3- human PBL. After expansion in rIL-2, all clones were able to lyse the NK-sensitive target cell line K562. In contrast, lysis of fresh tumor cells was achieved almost exclusively by CD3- clones. To test whether a known TCR-CD3 complex may be involved in MHC-unrestricted cytotoxicity, total RNA from nine CD3+ and 11 CD3- clones was isolated and hybridized with DNA probes for the TCR alpha-, beta-, and gamma-chains and for the CD3 gamma-, delta-, and epsilon-chains. TCR gamma transcripts were present at high levels in CD3+CD4- CD8- clones but were undetectable in all CD3- clones. Lysis of fresh tumor cells is an activity which can be independent of the TCR alpha beta and TCR gamma complexes because the CD3- clones did not express these TCR genes. Interestingly, all CD3- clones expressed CD3 epsilon transcripts, but not CD3 gamma- or delta-transcripts. CD3- lymphokine-activated cytotoxic cells may therefore be derived from immature T cells which do not yet express a complete CD3 complex. The CD3 epsilon chain, if expressed in CD3- cells in association with other molecules, could be involved in the activation and lytic function of these MHC-unrestricted cytotoxic cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894394

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Characteristics and contributions of defective, ecotropic, and mink cell focus-inducing viruses involved in a retrovirus-induced immunodeficiency syndrome of mice.

Authors:  S K Chattopadhyay; D N Sengupta; T N Fredrickson; H C Morse; J W Hartley
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  An unusual form of alternative splicing in the HLA-DNA gene.

Authors:  S Rosen-Bronson; E O Long
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

3.  Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells.

Authors:  P Anderson; M Caligiuri; C O'Brien; T Manley; J Ritz; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

4.  DNase I-defined chromatin configuration of the human CD3 gene cluster.

Authors:  A Tunnacliffe
Journal:  Nucleic Acids Res       Date:  1990-02-11       Impact factor: 16.971

5.  HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells.

Authors:  S Jacobson; R P Sekaly; C L Jacobson; H F McFarland; E O Long
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

Review 6.  T cell targeting in cancer therapy.

Authors:  R L Bolhuis; E Sturm; E Braakman
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 7.  Murine natural killer cell differentiation: past, present, and future.

Authors:  T A Moore; M Bennett; V Kumar
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

8.  Chimerism and tolerance to host and donor in severe combined immunodeficiencies transplanted with fetal liver stem cells.

Authors:  R Bacchetta; B A Vandekerckhove; J L Touraine; M Bigler; S Martino; L Gebuhrer; J E de Vries; H Spits; M G Roncarolo
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

9.  A block in both early T lymphocyte and natural killer cell development in transgenic mice with high-copy numbers of the human CD3E gene.

Authors:  B Wang; C Biron; J She; K Higgins; M J Sunshine; E Lacy; N Lonberg; C Terhorst
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

10.  Driving adenovirus type 12-transformed BALB/c mouse cells to express high levels of class I major histocompatibility complex proteins enhances, rather than abrogates, their tumorigenicity.

Authors:  S Soddu; A M Lewis
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.